Clinical Trial Update: Docetaxel in Non Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Sanofi-sponsored Phase 2 trial evaluating docetaxel for non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Sanofi | Conditions: Lung Neoplasms | Phase 2 | Status: COMPLETED